# US 10,245,285 B2 · Blood plasma and plasma fractions as therapy for tumor growth and progression

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,245,285 B2
- Document ID: US10245285B2
- Status: Granted
- Kind: B2
- Application number: 15/499,697
- Filed: 2017-04-27
- Published: 2017-11-30
- Granted: 2019-04-02
- Earliest claimed: 2016-04-28
- Assignees: Alkahest, Inc.
- Applicants: Alkahest, Inc.
- Inventors: Steven P. Braithwaite; S. Sakura Minami; Joseph McCracken
- Web page: https://patentgrep.com/patent/US10245285B2

## CPC

- A61K 35/16: Blood plasma; Blood serum (umbilical cord blood A61K35/51)
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to treating individuals with cancer by using blood plasma or blood plasma fractions as treatment.

## Claims

### Claim 1

A method of treating a subject for thymic cancer, the method comprising:
administering an effective amount of a blood plasma product to the subject diagnosed with thymic cancer to treat the subject for thymic cancer.

### Claim 2 (depends on 1)

The method of claim 1, wherein the blood plasma product is a young plasma.

### Claim 3 (depends on 1)

The method of claim 1, wherein the blood plasma product is a Plasma Fraction.

### Claim 4 (depends on 3)

The method of claim 3, wherein the Plasma Fraction is a Plasma Protein Fraction.

### Claim 5 (depends on 4)

The method of claim 4, wherein the Plasma Protein Fraction is a commercially available Plasma Protein Fraction.

### Claim 6 (depends on 3)

The method of claim 3, wherein the Plasma Fraction is a protein-enriched plasma protein product.

### Claim 7 (depends on 3)

The method of claim 3, wherein the Plasma Fraction is substantially devoid of one of the group selected from: a clotting factor or IgM.

### Claim 8 (depends on 7)

The method of claim 7, wherein the Plasma Fraction is substantially devoid of a clotting factor.

### Claim 9 (depends on 7)

The method of claim 7, wherein the Plasma Fraction is substantially of IgM.

### Claim 10

A method of treating a subject for thymic cancer, the method comprising:
administering an effective amount of a donor derived blood plasma product to the subject diagnosed with thymic cancer to treat the subject for thymic cancer.

### Claim 11 (depends on 10)

The method according to claim 10, wherein the blood plasma product is young plasma.

### Claim 12 (depends on 10)

The method according to claim 10, wherein the blood plasma product is a Plasma Fraction.

### Claim 13 (depends on 12)

The method of claim 12, wherein the Plasma Fraction is a Plasma Protein Fraction.

### Claim 14 (depends on 13)

The method of claim 13, wherein the Plasma Protein Fraction is a commercially available Plasma Protein Fraction.

### Claim 15 (depends on 12)

The method of claim 12, wherein the Plasma Fraction is a protein-enriched plasma protein product.

### Claim 16 (depends on 12)

The method of claim 12, wherein the Plasma Fraction is substantially devoid of one of the group selected from: a clotting factor or IgM.

### Claim 17 (depends on 16)

The method of claim 16, wherein the Plasma Fraction is substantially devoid of a clotting factor.

### Claim 18 (depends on 16)

The method of claim 16, wherein the Plasma Fraction is substantially devoid of IgM.